REV-ERB ligands for treatment of anxiety disorders

用于治疗焦虑症的 REV-ERB 配体

基本信息

  • 批准号:
    8578608
  • 负责人:
  • 金额:
    $ 83.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-04-01 至 2013-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Dysregulation of the circadian rhythm is associated with several disorders of the nervous system including anxiety disorders. Anxiety disorders are a serious medical illness affecting approximately 40 million adults in the United States. Benzodiazepenes are the most commonly utilized anxiolytic drugs, but their use is associated with significant side effects including sedation, tolerance and potential for abuse. There are a number of anxiolytic drugs that are now available, but these also are less than optimal. Thus, there is a clear unmet medical need for additional classes of therapeutics to treat these disorders. This proposed research is based on our recent discovery that we can modulate the circadian rhythm in vivo with synthetic ligands for a particular nuclear receptor (NR), REV-ERB. REV-ERBalpha is an NR that has a well-characterized role in the regulation of the circadian rhythm. We have found that REV-ERB agonists that we have designed that has the ability to modulate the circadian rhythm in vivo also display anxiolytic activity in mice. Interestingly, thes compounds display no sedative activity at anxiolytic doses. The REV-ERB agonists we have developed are the first with sufficient in vivo exposure to allow evaluation of its effects in animals; however, their pharmacodynamic and pharmcokinetic properties are far from optimal. We hypothesize that optimized synthetic REV-ERB ligands will have utility in treatment of anxiety disorders. We will address this hypothesis by focusing on the following specific aims: 1) Optimize the pharmacodynamic and pharmacokinetic properties of synthetic REV-ERB ligands for use as anxiolytic agents, 2) Evaluate the ability of synthetic REV- ERB ligands for their abiliy to modulate circadian behavior/physiology in vivo, 3) Optimize the anxiolytic activity of REV-ERB agonists in vivo and characterize their sedative activity and potential for abuse. We have now developed a series of very potent and efficacious REV-ERB agonists that have properties that will allow for evaluation of these compounds in animal models of disease. Thus, our proposed research is highly innovative and has the potential to have high impact since this work may lead to novel drugs for the treatment of anxiety disorders as well as other behavioral disorders.
描述(由申请人提供):昼夜节律失调与包括焦虑症在内的几种神经系统疾病有关。焦虑症是一种严重的医学疾病,影响着美国约4000万成年人。苯二氮卓类是最常用的抗焦虑药物,但其使用与显著的副作用相关,包括镇静、耐受性和滥用的可能性。现在有许多抗焦虑药物可用,但这些药物也不是最佳的。因此,对于治疗这些病症的其他类别的治疗剂存在明显未满足的医学需求。这项拟议的研究是基于我们最近的发现,我们可以调节体内的昼夜节律与合成配体的一个特定的核受体(NR),REV-ERB。REV-ERB α是一种NR,在昼夜节律调节中具有良好的特征化作用。我们已经发现,我们设计的具有调节体内昼夜节律能力的REV-ERB激动剂在小鼠中也显示出抗焦虑活性。有趣的是,这些化合物在抗焦虑剂量下不显示镇静活性。我们开发的REV-ERB激动剂是第一个具有足够的体内暴露以允许在动物中评价其作用的激动剂;然而,它们的药效学和药代动力学性质远不是最佳的。我们假设,优化的合成REV-ERB配体将在治疗焦虑症的效用。我们将通过关注以下具体目标来解决这一假设:1)优化用作抗焦虑剂的合成REV-ERB配体的药效学和药代动力学性质,2)评价合成REV-ERB配体在体内调节昼夜节律行为/生理学的能力,3)优化REV-ERB激动剂的体内抗焦虑活性,并表征其镇静活性和滥用潜力。我们现在已经开发了一系列非常强效和有效的REV-ERB激动剂,这些激动剂具有允许在动物疾病模型中评估这些化合物的特性。因此,我们提出的研究是高度创新的,并有可能产生很大的影响,因为这项工作可能导致治疗焦虑症以及其他行为障碍的新药。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Thomas P Burris其他文献

How to Make Glucocorticoids Safer.
PPARα ligands make memories
过氧化物酶体增殖物激活受体α配体形成记忆
  • DOI:
    10.1038/nchembio.2241
  • 发表时间:
    2016-11-15
  • 期刊:
  • 影响因子:
    13.700
  • 作者:
    Thomas P Burris
  • 通讯作者:
    Thomas P Burris

Thomas P Burris的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Thomas P Burris', 18)}}的其他基金

Exercise Mimetics for Dementia and Alzheimer's Disease
治疗痴呆和阿尔茨海默病的模拟运动
  • 批准号:
    10586188
  • 财政年份:
    2023
  • 资助金额:
    $ 83.45万
  • 项目类别:
Targeting REV-ERB to treat Alzheimer's disease
靶向 REV-ERB 治疗阿尔茨海默病
  • 批准号:
    10675294
  • 财政年份:
    2019
  • 资助金额:
    $ 83.45万
  • 项目类别:
ERRgamma Agonists to Treat Muscular Dystrophy
ERRgamma 激动剂治疗肌营养不良症
  • 批准号:
    9176946
  • 财政年份:
    2016
  • 资助金额:
    $ 83.45万
  • 项目类别:
Treatment of Alcohol Induced Hepatic Injury with REV-ERB Ligands
用 REV-ERB 配体治疗酒精引起的肝损伤
  • 批准号:
    8898423
  • 财政年份:
    2012
  • 资助金额:
    $ 83.45万
  • 项目类别:
REV-ERB ligands for treatment of anxiety disorders
用于治疗焦虑症的 REV-ERB 配体
  • 批准号:
    8915743
  • 财政年份:
    2012
  • 资助金额:
    $ 83.45万
  • 项目类别:
REV-ERB ligands for treatment of anxiety disorders
用于治疗焦虑症的 REV-ERB 配体
  • 批准号:
    8237792
  • 财政年份:
    2012
  • 资助金额:
    $ 83.45万
  • 项目类别:
Treatment of Alcohol Induced Hepatic Injury with REV-ERB Ligands
用 REV-ERB 配体治疗酒精引起的肝损伤
  • 批准号:
    8444102
  • 财政年份:
    2012
  • 资助金额:
    $ 83.45万
  • 项目类别:
REV-ERB ligands for treatment of anxiety disorders
用于治疗焦虑症的 REV-ERB 配体
  • 批准号:
    9116001
  • 财政年份:
    2012
  • 资助金额:
    $ 83.45万
  • 项目类别:
Development of ROR ligands for treatment of circadian rhythm disorders
开发用于治疗昼夜节律紊乱的 ROR 配体
  • 批准号:
    8370510
  • 财政年份:
    2010
  • 资助金额:
    $ 83.45万
  • 项目类别:
Development of ROR ligands for treatment of circadian rhythm disorders
开发用于治疗昼夜节律紊乱的 ROR 配体
  • 批准号:
    8209001
  • 财政年份:
    2010
  • 资助金额:
    $ 83.45万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 83.45万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 83.45万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 83.45万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 83.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 83.45万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 83.45万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 83.45万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 83.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 83.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 83.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了